Shares of Arcturus Therapeutics (ARCT) dropped by a staggering 30.46% in 30 days from $41.5 to $28.86 at 23:32 EST on Sunday, after four consecutive sessions in a row of losses. NASDAQ Composite (ARCT) is rising 2.32% to $13,429.98, after two sequential sessions in a row of gains.

Arcturus Therapeutics’s last close was $25.79, 349.45% under its 52-week high of $129.71.

Arcturus Therapeutics’s Sales

Arcturus Therapeutics’s sales growth is a negative 4% for the current quarter and a decline by 28% for the next. The company’s growth estimates for the ongoing quarter and the next is a negative 86.6% and a negative 163.6%, respectively.

Arcturus Therapeutics’s Revenue

Year-on-year quarterly revenue growth declined by 24.6%, now sitting on 9.54M for the twelve trailing months.

Arcturus Therapeutics’s Stock Yearly Top and Bottom Value

Arcturus Therapeutics’s stock is valued at $28.86 at 23:32 EST, way below its 52-week high of $129.71 and way above its 52-week low of $13.09.

Arcturus Therapeutics’s Moving Average

Arcturus Therapeutics’s worth is way below its 50-day moving average of $50.01 and way below its 200-day moving average of $62.10.

More news about Arcturus Therapeutics (ARCT).


Please enter your comment!
Please enter your name here